Preferred Label : Anti-ILT2 Monoclonal Antibody BND-22;
NCIt definition : A humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the inhibitory
immune checkpoint receptor Ig-like transcript 2 (ILT2; leukocyte immunoglobulin-like
receptor subfamily B member 1; LILRB1; leukocyte immunoglobulin-like receptor 1; LIR1;
monocyte/macrophage immunoglobulin-like receptor 7; MIR-7; CD85j), with potential
immunomodulating and antineoplastic activities. Upon administration, anti-ILT2 monoclonal
antibody BND-22 targets and binds to ILT2. This prevents the binding of ILT2 ligands,
including the immunosuppressive MHC molecule HLA class I histocompatibility antigen,
alpha chain G (HLA-G; human leukocyte antigen G), to the ILT2 receptor and prevents
ILT2-mediated signaling. This inhibits ILT2-mediated immune suppression, thereby activating
both innate and adaptive immune responses. This may activate anti-tumor immune responses.
ILT2, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript
(ILT) family of proteins, is expressed on both innate and adaptive immune cells. HLA-G,
an immune checkpoint normally expressed at the maternal-fetal interface, is expressed
across multiple tumor types and plays a key role in cancer immune evasion.;
Molecule name : BND-22; BND 22;
NCI Metathesaurus CUI : CL1662081;
Origin ID : C179566;
UMLS CUI : C5555776;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
